Protalix BioTherapeutics (PLX) EBT Margin (2010 - 2026)
Protalix BioTherapeutics' quarterly EBT Margin came in at 62.64% in Q1 2026, up 9954.0% year-on-year from N/an in Q1 2025, and up 252.5% quarter-over-quarter from 41.08% in Q4 2025.
Protalix BioTherapeutics has reported EBT Margin for 17 years, with the latest figure at 62.64% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 9954.0% year-over-year to 62.64%; the trailing twelve-month figure through Mar 2026 stood at 26.57% (up 1033.0% YoY), and the FY2025 full-year result was 8.68%, down 2498.0% from the prior year.
- EBT Margin for Q1 2026 stood at 62.64%, up from 41.08% in the prior quarter.
- The five-year high for EBT Margin was 65.12% in Q4 2024, with the low at 210.31% in Q4 2023.
- Average EBT Margin over 5 years is 23.19%, with a median of 16.86% recorded in 2024.
- Year-over-year, EBT Margin slumped 17306 bps in 2023 and jumped 27543 bps in 2024.
- Tracing PLX's EBT Margin over 5 years: stood at 37.25% in 2022, then tumbled by 465 bps to 210.31% in 2023, then soared by 131 bps to 65.12% in 2024, then plunged by 163 bps to 41.08% in 2025, then surged by 252 bps to 62.64% in 2026.
- The last three EBT Margin figures came in at 62.64% (Q1 2026), 41.08% (Q4 2025), and 12.54% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 62.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.64% |
| Dec 31, 2025 | -41.08% |
| Sep 30, 2025 | 12.54% |
| Jun 30, 2025 | 4.22% |
| Mar 31, 2025 | -36.90% |
| Dec 31, 2024 | 65.12% |
| Sep 30, 2024 | 21.40% |
| Jun 30, 2024 | -16.86% |
| Mar 31, 2024 | -126.28% |
| Dec 31, 2023 | -210.31% |
| Sep 30, 2023 | -16.62% |
| Jun 30, 2023 | 56.01% |
| Mar 31, 2023 | -30.62% |
| Dec 31, 2022 | -37.25% |
| Sep 30, 2022 | -25.15% |
| Jun 30, 2022 | -60.94% |
| Mar 31, 2022 | -14.21% |
| Dec 31, 2021 | -77.37% |
| Sep 30, 2021 | -35.63% |
| Jun 30, 2021 | -176.89% |
| Mar 31, 2021 | -51.78% |
| Dec 31, 2020 | 1.63% |
| Sep 30, 2020 | -42.22% |
| Jun 30, 2020 | -38.19% |
| Mar 31, 2020 | 6.76% |
| Dec 31, 2019 | 0.79% |
| Sep 30, 2019 | -25.22% |
| Jun 30, 2019 | -63.25% |
| Mar 31, 2019 | -71.41% |
| Dec 31, 2018 | -315.09% |
| Sep 30, 2018 | -837.41% |
| Jun 30, 2018 | -425.57% |
| Mar 31, 2018 | -161.89% |
| Dec 31, 2017 | -583.22% |
| Sep 30, 2017 | -152.07% |
| Jun 30, 2017 | -217.84% |
| Mar 31, 2017 | -513.49% |
| Dec 31, 2016 | -490.00% |
| Sep 30, 2016 | -161.84% |
| Jun 30, 2016 | -612.32% |
| Mar 31, 2016 | -1,291.31% |
| Sep 30, 2015 | -451.50% |
| Jun 30, 2015 | -466.02% |
| Mar 31, 2015 | -386.58% |
| Mar 31, 2014 | -110.26% |
| Dec 31, 2013 | 210.63% |
| Sep 30, 2013 | -247.15% |
| Jun 30, 2013 | -304.51% |
| Mar 31, 2013 | -124.52% |
| Dec 31, 2012 | -867.49% |
| Sep 30, 2012 | -149.30% |
| Jun 30, 2012 | 36.84% |
| Mar 31, 2012 | -157.08% |
| Dec 31, 2011 | -375.02% |
| Sep 30, 2011 | -774.47% |
| Jun 30, 2011 | -1,815.18% |
| Mar 31, 2011 | -122.04% |
| Dec 31, 2010 | -752.38% |
| Sep 30, 2010 | -89.45% |
| Jun 30, 2010 | -889.57% |